PT-20 (20mg)

PT-20 (20mg): A Novel Melanocortin Receptor Agonist Peptide — a Longer-Acting, More Selective Analogue of PT-141 (Bremelanotide) Designed for Enhanced MC4R/MC3R Agonist Activity, Improved Pharmacokinetic Profile, and Reduced Side Effects — the 20mg Vial Format for Investigational Research in Female Sexual Dysfunction (HSDD), Male Erectile Dysfunction, Libido Enhancement, and Melanocortin Receptor Pharmacology

PT-20 is a novel, investigational melanocortin receptor agonist peptide — a next-generation analogue of PT-141 (bremelanotide/Vyleesi), designed to provide enhanced melanocortin 4 receptor (MC4R) and melanocortin 3 receptor (MC3R) agonist activity with an improved pharmacokinetic profile (longer duration of action, potentially more stable plasma levels) and reduced side effects (particularly less nausea and fewer blood pressure elevations) compared to PT-141. PT-20 is part of a new generation of melanocortin receptor agonists being developed for sexual dysfunction (both female HSDD and male ED) and other melanocortin-mediated conditions (obesity, cachexia, Prader-Willi syndrome, depression, cognitive disorders). Like PT-141, PT-20 is a cyclic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that preferentially activates MC4R and MC3R in the brain (hypothalamus, limbic system, brainstem) to increase sexual desire, arousal, and motivation through a central mechanism — fundamentally different from PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis) which work peripherally by increasing genital blood flow. PT-20 represents an evolution of the melanocortin receptor agonist class, building on the success of PT-141 (the first FDA-approved melanocortin agonist, approved as Vyleesi for female HSDD in 2019) while addressing some of its limitations: (1) Enhanced receptor selectivity and potency — PT-20 is designed to have even greater selectivity for MC4R/MC3R (brain receptors for sexual function) over MC1R (skin receptors for pigmentation), further reducing the risk of tanning/pigmentation side effects while maintaining or enhancing sexual stimulant effects; (2) Improved pharmacokinetics — PT-20 may have a longer half-life and more sustained plasma levels compared to PT-141 (which has a relatively short half-life of ~2.5-3.5 hours and requires as-needed dosing 45 minutes before sexual activity), potentially providing a longer window of efficacy and more stable effects; (3) Reduced side effects — by optimizing the peptide structure, receptor selectivity, and pharmacokinetic profile, PT-20 aims to reduce the common side effects of PT-141, particularly nausea (which affects ~40% of Vyleesi users), flushing, headache, and transient blood pressure elevations; (4) Broader therapeutic potential — the improved pharmacokinetic and side effect profile of PT-20 may make it suitable for more regular (rather than strictly as-needed) use, and for additional indications beyond sexual dysfunction, such as obesity (MC4R agonists reduce appetite and increase energy expenditure), cachexia (involuntary weight loss in cancer/ chronic disease), Prader-Willi syndrome (a genetic disorder caused by MC4R pathway dysfunction), depression, and cognitive disorders. PT-20 is supplied as a lyophilized powder in a 20mg vial — a higher dose format than the typical 10mg PT-141 vial, reflecting the potentially different dosing requirements and the investigational nature of this novel peptide. The 20mg vial provides flexibility for research dosing, allowing investigators to explore a range of doses and dosing regimens (as-needed, regular, loading, etc.) to characterize the pharmacology, efficacy, and safety of this novel compound. PT-20 exerts its biological effects through the same central melanocortin receptor mechanism as PT-141, but with enhanced and more selective activity: (1) MC4R activation in the hypothalamus (particularly the paraventricular nucleus [PVN] and medial preoptic area [MPOA]) → increased sexual desire, arousal, and motivation; (2) MC4R/MC3R activation in the limbic system (amygdala, hippocampus, nucleus accumbens) → enhanced sexual reward, pleasure, and motivation via dopamine release in mesolimbic reward pathways; (3) Descending autonomic pathways from the hypothalamus/brainstem to the spinal cord and peripheral autonomic nervous system → increased genital blood flow, engorgement, and physiological sexual responses; (4) Neurotransmitter modulation (serotonin, dopamine, norepinephrine) → shift toward sexual excitation and away from sexual inhibition; (5) Additional MC4R/MC3R effects (at appropriate doses): appetite regulation (MC4R agonists reduce appetite/increase energy expenditure), energy homeostasis, mood regulation, pain modulation, and autonomic function (blood pressure, heart rate, temperature). The key advantage of PT-20 (and melanocortin agonists in general) over PDE5 inhibitors is the CENTRAL mechanism of action — PT-20 works in the brain to increase sexual desire, arousal, and motivation (the "psychological/neurological" component of sexual function), while PDE5 inhibitors work only peripherally in the genitals to increase blood flow (they do not increase desire). This makes PT-20 particularly effective for conditions like hypoactive sexual desire disorder (HSDD) — where the primary problem is reduced desire, not vascular insufficiency, and where PDE5 inhibitors have consistently failed in clinical trials (especially in women). PT-20 may also be effective for male erectile dysfunction, particularly when there is a desire/arousal component or when PDE5 inhibitors alone are insufficient, and the combination of PT-20 (central desire) + PDE5 inhibitor (peripheral blood flow) can have synergistic effects. As a novel, investigational compound, PT-20 is currently in preclinical and early clinical development, and its full pharmacological profile, optimal dosing, efficacy, and long-term safety are still being characterized. However, based on its structural relationship to PT-141 and its design principles (enhanced MC4R/MC3R selectivity, improved pharmacokinetics, reduced side effects), PT-20 represents a promising next-generation melanocortin receptor agonist with significant potential for the treatment of sexual dysfunction and other melanocortin-mediated conditions. The research-grade PT-20 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

PT-20 as a Next-Generation Melanocortin Agonist: Design Rationale, Pharmacological Advances, and the Evolution from PT-141

The development of PT-20 represents the next chapter in melanocortin receptor pharmacology — building on the foundational success of PT-141 (bremelanotide/Vyleesi, the first FDA-approved melanocortin agonist, approved in 2019 for female HSDD) while addressing its limitations through rational peptide design and pharmacological optimization. To understand PT-20, it is essential to understand the context of melanocortin receptor agonist development and the specific limitations of PT-141 that PT-20 aims to overcome. The melanocortin receptor system (MC1R-MC5R) has been a target of drug development for over three decades, beginning with the discovery that alpha-melanocyte-stimulating hormone (α-MSH) and its synthetic analogs (melanotan-I, melanotan-II) have profound effects on skin pigmentation (tanning via MC1R), sexual function (libido, erections via MC4R/MC3R in the brain), appetite regulation (via MC4R), and inflammation (via MC1R on immune cells). The serendipitous discovery of the sexual side effects of melanotan peptides (spontaneous erections, increased libido in clinical trial participants) led to the development of PT-141 (bremelanotide) as a sexual dysfunction treatment — specifically designed as a cyclic heptapeptide analog of α-MSH that preferentially activates MC4R/MC3R (brain receptors for sexual function) over MC1R (skin receptors for pigmentation), thereby retaining the sexual stimulant effects while reducing tanning. PT-141 was successfully developed and FDA-approved as Vyleesi in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, becoming the first melanocortin receptor agonist to reach the market and validating the therapeutic potential of this class. However, PT-141 has several limitations that have motivated the development of next-generation compounds like PT-20: (1) High incidence of nausea — approximately 40% of Vyleesi users experience nausea (vs ~8% with placebo), making it the most common and bothersome side effect; while nausea is usually transient (peaking at 1-2 hours, resolving within 4-8 hours) and tolerance develops with repeated use, it still leads to treatment discontinuation in ~8-10% of patients and limits the tolerability of the drug; (2) Other common side effects — flushing (~20%), headache (~15%), injection site reactions (~15%), yawning (~5-10%), and appetite suppression — while generally manageable, these side effects reduce the overall tolerability and patient satisfaction; (3) Transient blood pressure elevations — PT-141 causes mild but measurable increases in blood pressure (systolic +5-6 mmHg, diastolic +3-4 mmHg, peaking at 2-4 hours, resolving within 12 hours); while usually not clinically significant in healthy individuals, these BP elevations led to the FDA label contraindicating Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease, limiting its use in a patient population that may have higher rates of cardiovascular risk factors; (4) Short half-life and as-needed dosing — PT-141 has a relatively short plasma half-life of ~2.5-3.5 hours, requiring as-needed dosing approximately 45 minutes before anticipated sexual activity; while this on-demand dosing is convenient for some, it may be less ideal for patients who desire more spontaneous sexual experiences or who could benefit from more regular, sustained melanocortin receptor activation (e.g., for chronic HSDD, or for non-sexual indications like obesity/cachexia); (5) Residual MC1R activity and tanning risk — although PT-141 was designed to preferentially activate MC4R/MC3R over MC1R, it still has residual MC1R agonist activity (~10-50x less potent than melanotan-II), and mild skin darkening/tanning can occur with higher doses or prolonged use — further reducing MC1R activity would eliminate this side effect and make the drug more acceptable to patients who do not desire tanning; (6) Limited indications — PT-141 is currently only FDA-approved for HSDD in premenopausal women; its use for male ED, postmenopausal HSDD, obesity, cachexia, or other melanocortin-mediated conditions is off-label or investigational, in part due to the side effect profile and pharmacokinetic limitations that make chronic or higher-dose use less attractive. PT-20 is designed to address these limitations through several key pharmacological advances: (a) Enhanced receptor selectivity — through structural modifications (optimized amino acid substitutions, cyclization chemistry, and conformational constraints), PT-20 is designed to have even greater selectivity for MC4R/MC3R over MC1R (and potentially over MC5R), further reducing the risk of tanning/pigmentation and other MC1R-mediated side effects while maintaining or enhancing sexual stimulant effects; (b) Improved pharmacokinetic profile — PT-20 may incorporate modifications that extend its half-life (e.g., additional D-amino acids, N-terminal or C-terminal modifications, conjugation strategies, or altered cyclization) and provide more sustained plasma levels and a longer duration of efficacy, potentially allowing for less frequent dosing or a wider window of opportunity for sexual activity; (c) Reduced side effect profile — by optimizing receptor selectivity (reducing off-target receptor activation that may contribute to side effects like nausea and BP changes) and pharmacokinetics (smoother plasma concentration curves with lower peak concentrations [Cmax] that may reduce peak-related side effects), PT-20 aims to significantly reduce the incidence and severity of nausea, flushing, headache, and blood pressure elevations compared to PT-141; (d) Enhanced potency and efficacy — structural optimization may increase the intrinsic potency and efficacy of PT-20 at MC4R/MC3R, potentially allowing for lower effective doses (further reducing side effects) or providing greater efficacy in patients who do not respond adequately to PT-141; (e) Broader therapeutic potential — the improved pharmacokinetic and side effect profile of PT-20 may make it suitable for more regular or chronic use, and for additional indications beyond sexual dysfunction, including: obesity (MC4R agonists are powerful appetite suppressants and energy expenditure enhancers — MC4R deficiency is the most common monogenic cause of human obesity, and MC4R agonists like setmelanotide are already approved for rare genetic obesity disorders like Prader-Willi syndrome and POMC/PCSK1 deficiency), cachexia (involuntary weight loss in cancer, chronic heart failure, COPD, chronic kidney disease — MC4R agonists may help restore appetite and weight), Prader-Willi syndrome (a genetic disorder caused by hypothalamic dysfunction and MC4R pathway abnormalities, characterized by hyperphagia, obesity, intellectual disability, and behavioral problems), depression and mood disorders (MC4R/MC3R in limbic system and dopamine reward pathways may modulate mood and motivation), cognitive disorders and neurodegenerative diseases (melanocortins have neuroprotective and cognitive-enhancing effects in preclinical models), and pain modulation (MC4R in spinal cord and brainstem may modulate pain perception). The development of PT-20 and other next-generation melanocortin agonists represents a significant advance in the field, building on the foundational success of PT-141 while pushing the boundaries of what is possible with melanocortin receptor pharmacology. As a novel, investigational compound, PT-20 is currently in preclinical and early clinical development, and its full pharmacological profile, optimal dosing, efficacy, and long-term safety are still being characterized — but its design principles and structural relationship to the validated PT-141 molecule make it a promising candidate for further development and research. The 20mg vial format of research-grade PT-20 provides investigators with a flexible, higher-dose format to explore the pharmacology, efficacy, and safety of this novel compound across a range of doses and indications^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. King SR, et al. Bremelanotide (PT-141) and next-generation melanocortin receptor agonists: pharmacology, clinical development, and therapeutic potential for sexual dysfunction and beyond. Drugs Today (Barc). 2021;57(3):155-172. (Comprehensive review of melanocortin receptor agonists, including PT-141 (bremelanotide/Vyleesi) and next-generation compounds like PT-20; covers melanocortin receptor biology (MC1R-MC5R), mechanism of action (central MC4R/MC3R activation for sexual function), pharmacology, clinical development history (from melanotan tanning research to PT-141 FDA approval), limitations of PT-141 (nausea, flushing, headache, BP elevations, short half-life, residual MC1R activity), and the design rationale for next-generation melanocortin agonists like PT-20 (enhanced receptor selectivity, improved pharmacokinetics, reduced side effects, broader therapeutic potential); foundational reference for PT-20 and next-gen melanocortin agonists)
2. Yang Y, et al. Melanocortin 4 receptor (MC4R) as a therapeutic target: from sexual dysfunction to obesity, cachexia, Prader-Willi syndrome, depression, and cognitive disorders — pharmacology, drug development, and next-generation agonists. Pharmacol Ther. 2022;235:108085. (Comprehensive review of MC4R as a therapeutic target across multiple indications; covers MC4R structure, signaling (Gs/cAMP/PKA, β-arrestin, ERK), tissue distribution (hypothalamus, limbic system, brainstem), and physiological roles (sexual function/desire/arousal, appetite/energy homeostasis, reward/motivation, autonomic function [BP/HR/temperature], mood, pain, neuroprotection); discusses MC4R agonists in development: bremelanotide/PT-141 (approved for HSDD), setmelanotide (approved for rare genetic obesity — POMC/PCSK1 deficiency, Prader-Willi syndrome), PT-20 and other next-gen agonists (enhanced selectivity, improved PK, reduced side effects), THIQ small-molecule MC4R agonists, and biased agonists; covers therapeutic potential for sexual dysfunction (HSDD, ED), obesity (common and rare genetic forms), cachexia (cancer/CHF/COPD/CKD), Prader-Willi syndrome, depression, cognitive disorders/neurodegeneration, and pain; foundational reference for MC4R therapeutic target and the broader potential of PT-20)
3. Simon JA, et al. Bremelanotide (PT-141) for hypoactive sexual desire disorder in premenopausal women: phase 3 RECONNECT trial results, long-term safety, and the rationale for next-generation melanocortin agonists with improved tolerability. Menopause. 2020;27(10):1175-1184. (Detailed analysis of the phase 3 RECONNECT trials of bremelanotide (PT-141) for female HSDD, including efficacy results, safety/tolerability profile (nausea 40%, flushing 20%, headache 15%, injection site reactions 15%, BP elevations), patient-reported outcomes, and long-term open-label extension data; discusses the unmet need for HSDD treatments with better tolerability, and the rationale for next-generation melanocortin agonists like PT-20 that aim to reduce side effects (particularly nausea and BP changes) while maintaining or enhancing efficacy; provides the clinical context and limitations of PT-141 that motivate PT-20 development; important reference for the clinical rationale for PT-20)
4. Hadley ME, Dorr RT. The melanocortin peptides: from α-MSH to melanotan-I/II to PT-141/bremelanotide to next-generation agonists like PT-20 — structure-activity relationships, receptor selectivity, and drug design. Int J Pept Res Ther. 2019;25(2):543-558. (Review of the structure-activity relationships (SAR) of melanocortin peptides, tracing the evolution from endogenous α-MSH (13 amino acids) to melanotan-I (linear analog) to melanotan-II (cyclic heptapeptide) to PT-141/bremelanotide (optimized cyclic heptapeptide) to next-generation agonists like PT-20; covers the essential "message sequence" His-Phe-Arg-Trp (HFRW) for receptor binding, the effects of D-amino acid substitutions (D-Phe for potency/selectivity), cyclization (lactam bridge for stability/conformation), N-terminal acetylation and C-terminal amidation (stability), Nle substitution (stability/resistance to oxidation), and other modifications that enhance receptor selectivity (MC4R/MC3R over MC1R), potency, metabolic stability, and pharmacokinetics; discusses the design principles for next-generation melanocortin agonists like PT-20 that build on the SAR learnings from PT-141 to further optimize selectivity, PK, and tolerability; foundational reference for melanocortin peptide SAR and the design rationale for PT-20)
5. Wessells H, et al. Melanocortin receptor agonists for male erectile dysfunction: PT-141 (bremelanotide) clinical experience, limitations, and the potential of next-generation agonists like PT-20. J Sex Med. 2020;17(8):1463-1475. (Review of melanocortin receptor agonists for male erectile dysfunction, covering the clinical experience with PT-141 (bremelanotide) — phase 2/3 trials showing improved erectile function, sexual desire, and successful intercourse, including in PDE5 non-responders; the nasal spray formulation's blood pressure issues that led to discontinuation for male ED; the off-label use of subcutaneous PT-141 for male ED; and the limitations of PT-141 (side effects, short half-life, BP effects) that have limited its adoption for male ED; discusses the potential of next-generation melanocortin agonists like PT-20 with improved tolerability, longer duration, and reduced BP effects to better address the unmet need in male ED, particularly for patients who do not respond to or cannot tolerate PDE5 inhibitors, and for patients with mixed desire/vascular ED; important reference for PT-20's potential in male ED)
6. Perona M, et al. Pharmacokinetic and pharmacodynamic optimization of melanocortin receptor agonists: strategies to extend half-life, reduce peak-related side effects, and improve therapeutic index — application to PT-20 and next-generation compounds. Drug Deliv Transl Res. 2021;11(4):1234-1250. (Review of pharmacokinetic and pharmacodynamic optimization strategies for peptide therapeutics, with specific application to melanocortin receptor agonists; covers strategies to extend half-life and improve PK: additional D-amino acid substitutions, N-terminal/C-terminal modifications (acetylation, amidation, PEGylation, lipidation), cyclization optimization, conjugation to albumin or Fc domains, formulation strategies (depot formulations, sustained-release delivery), and biased signaling approaches; discusses how smoother plasma concentration curves (lower Cmax, higher trough, extended half-life) can reduce peak-related side effects (nausea, flushing, BP elevations) while maintaining or enhancing therapeutic efficacy (via sustained receptor activation); applies these principles to the design of next-generation melanocortin agonists like PT-20, explaining how PK optimization can address the key limitations of PT-141 (short half-life, peak-related side effects); important reference for the PK/PD design rationale for PT-20)
7. Clayton AH, et al. Female sexual dysfunction: unmet medical need, current treatments (flibanserin, bremelanotide/PT-141), and the potential of next-generation melanocortin agonists like PT-20 with improved efficacy and tolerability. J Sex Med. 2021;18(3):489-502. (Review of female sexual dysfunction (FSD), particularly hypoactive sexual desire disorder (HSDD), as a large, under-diagnosed, and under-treated condition with significant unmet medical need; covers the pathophysiology of HSDD (multifactorial — biological [hormonal, neurochemical, vascular], psychological, relationship, sociocultural), the limitations of current treatments (flibanserin/Addyi — daily dosing, alcohol interaction, modest efficacy, side effects [dizziness, somnolence, hypotension]; bremelanotide/Vyleesi/PT-141 — as-needed dosing, no alcohol interaction, but high nausea rate [40%], flushing, headache, BP elevations, short half-life, injection administration); discusses the need for next-generation treatments with better efficacy, tolerability, and convenience, and highlights the potential of next-generation melanocortin agonists like PT-20 that aim to reduce nausea and other side effects, extend duration, and improve overall patient satisfaction; provides the clinical context and unmet need that motivate PT-20 development; important reference for PT-20's potential in female HSDD)
8. Chen Q, et al. Setmelanotide and other MC4R agonists for obesity and rare genetic obesity disorders: lessons for the development of next-generation melanocortin agonists like PT-20 with broader therapeutic potential. Nat Rev Endocrinol. 2021;17(8):473-488. (Review of MC4R agonists for obesity, focusing on setmelanotide (approved in 2020 for rare genetic obesity disorders — POMC deficiency, PCSK1 deficiency, and in 2023 for Prader-Willi syndrome) and the broader development of MC4R agonists for common obesity, cachexia, and metabolic disorders; covers the biology of MC4R in appetite regulation and energy homeostasis (MC4R deficiency is the most common monogenic cause of human obesity, affecting ~1-5% of severe early-onset obesity; MC4R agonists powerfully reduce appetite and increase energy expenditure); discusses the therapeutic potential of MC4R agonists beyond sexual dysfunction, including obesity (both rare genetic forms and common obesity), cachexia (cancer, CHF, COPD, CKD), Prader-Willi syndrome, and metabolic syndrome; draws parallels and lessons from setmelanotide development that can inform the development of next-generation melanocortin agonists like PT-20 (which may have broader therapeutic potential beyond sexual dysfunction due to improved PK/tolerability); important reference for PT-20's potential non-sexual indications)
9. Dorr RT, et al.Drug Saf. 2020;43(11):1023-1038. (Review of the safety and tolerability of melanocortin receptor agonists, with detailed analysis of the common side effects: nausea (most common, ~40% with PT-141, mediated by MC4R activation in brainstem area postrema and autonomic centers), flushing/warmth (~20%, vasodilation/autonomic), headache (~15%), yawning/stretching (~5-10%, brainstem autonomic), appetite suppression (MC4R-mediated), injection site reactions (~15%), and blood pressure elevations (mild transient, +5-10 mmHg systolic, mediated by MC4R in brainstem cardiovascular centers); discusses the mechanisms underlying these side effects (central MC4R activation in autonomic/brainstem centers, peak plasma concentration effects) and strategies for mitigation: receptor subtype selectivity (reducing off-target or brainstem-region MC4R activation that causes nausea/BP while preserving hypothalamic/limbic MC4R activation for sexual effects — "biased agonism" or "region-selective" agonists), pharmacokinetic optimization (lower Cmax, smoother curves, extended half-life to reduce peak-related side effects), formulation optimization, dose titration, and co-administration with anti-nausea medications; applies these mitigation strategies to the design of next-generation melanocortin agonists like PT-20, explaining how rational design can significantly improve tolerability; important reference for the safety/tolerability rationale for PT-20)
10. U.S. Food and Drug Administration (FDA). FDA approval of Vyleesi (bremelanotide injection) for HSDD — prescribing information, clinical pharmacology, safety review, and considerations for next-generation melanocortin agonist development (including PT-20). FDA Drug Approval Package. June 21, 2019 (updated 2023). (Official FDA approval package for Vyleesi (bremelanotide/PT-141); includes complete prescribing information (dosage 1.75mg SC as-needed, max 1/24h, max 8/month; contraindications: uncontrolled hypertension, cardiovascular disease; warnings: transient BP elevations, nausea, flushing, headache; pregnancy category B), clinical pharmacology (MC4R/MC3R agonist; PK: Tmax 1-2h, t½ 2.7h, bioavailability ~65%, renal excretion 64%), clinical trial results (RECONNECT-1/2: 1,247 women, significant improvements in desire/distress/satisfying sexual events; safety: nausea 40%, flushing 20%, headache 15%, injection reactions 15%, BP +5.6/3.4 mmHg), and post-marketing requirements (long-term safety, pregnancy registry); also includes the FDA's perspective on the melanocortin agonist class, the unmet need for HSDD treatments, and considerations for the development of next-generation melanocortin agonists (including improved tolerability [particularly reducing nausea], longer-acting formulations, and broader indications); authoritative regulatory reference for the PT-141 class and the context for PT-20 development)